2024 Q2 Form 10-Q Financial Statement
#000143853324000020 Filed on May 06, 2024
Income Statement
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| Revenue | $54.12M | $41.37M |
| YoY Change | -9.35% | -27.41% |
| Cost Of Revenue | $2.061M | $1.504M |
| YoY Change | 3.57% | -70.65% |
| Gross Profit | $52.06M | $39.87M |
| YoY Change | -9.79% | -23.13% |
| Gross Profit Margin | 96.19% | 96.36% |
| Selling, General & Admin | $64.78M | $64.22M |
| YoY Change | 2.64% | -11.1% |
| % of Gross Profit | 124.44% | 161.08% |
| Research & Development | $54.33M | $49.42M |
| YoY Change | -18.9% | 558.93% |
| % of Gross Profit | 104.37% | 123.95% |
| Depreciation & Amortization | $10.35M | $9.880M |
| YoY Change | -25.6% | 3.51% |
| % of Gross Profit | 19.87% | 24.78% |
| Operating Expenses | $119.1M | $113.6M |
| YoY Change | -18.02% | 42.51% |
| Operating Profit | -$67.70M | -$139.2M |
| YoY Change | -22.7% | 59.96% |
| Interest Expense | $1.632M | $2.800M |
| YoY Change | -26.39% | -3.45% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$1.863M | $3.470M |
| YoY Change | 826.87% | 337.58% |
| Pretax Income | -$69.57M | -$135.8M |
| YoY Change | -18.7% | 57.41% |
| Income Tax | $85.00K | $191.0K |
| % Of Pretax Income | ||
| Net Earnings | -$70.41M | -$136.1M |
| YoY Change | -17.78% | 57.6% |
| Net Earnings / Revenue | -130.11% | -328.86% |
| Basic Earnings Per Share | -$0.91 | -$1.76 |
| Diluted Earnings Per Share | -$0.91 | -$1.76 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 76.13M shares | 76.10M shares |
| Diluted Shares Outstanding | 77.50M shares | 77.14M shares |
Balance Sheet
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $253.9M | $284.6M |
| YoY Change | -48.32% | -35.38% |
| Cash & Equivalents | $32.29M | $43.25M |
| Short-Term Investments | $221.7M | $241.4M |
| Other Short-Term Assets | $13.14M | $12.77M |
| YoY Change | 13.7% | -15.67% |
| Inventory | $42.98M | $42.31M |
| Prepaid Expenses | ||
| Receivables | $24.50M | $22.70M |
| Other Receivables | $0.00 | $0.00 |
| Total Short-Term Assets | $369.0M | $481.1M |
| YoY Change | -31.93% | -20.47% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $6.580M | $6.943M |
| YoY Change | -76.61% | -23.93% |
| Goodwill | $800.0K | $800.0K |
| YoY Change | -11.11% | -11.11% |
| Intangibles | $105.2M | $101.2M |
| YoY Change | -31.91% | -37.88% |
| Long-Term Investments | $0.00 | |
| YoY Change | ||
| Other Assets | $16.92M | $19.30M |
| YoY Change | 43.52% | 75.02% |
| Total Long-Term Assets | $182.1M | $182.5M |
| YoY Change | -6.29% | -10.26% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $369.0M | $481.1M |
| Total Long-Term Assets | $182.1M | $182.5M |
| Total Assets | $551.1M | $663.5M |
| YoY Change | -25.16% | -17.9% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $25.84M | $16.73M |
| YoY Change | 29.77% | -0.01% |
| Accrued Expenses | $79.64M | $139.6M |
| YoY Change | 22.23% | 62.75% |
| Deferred Revenue | $5.378M | $6.460M |
| YoY Change | -47.5% | -41.14% |
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $121.3M | $173.2M |
| YoY Change | -10.64% | 32.6% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $378.1M | $377.7M |
| YoY Change | 0.46% | 0.46% |
| Other Long-Term Liabilities | $16.64M | $16.38M |
| YoY Change | -84.57% | 80.62% |
| Total Long-Term Liabilities | $16.64M | $16.38M |
| YoY Change | -96.56% | 80.62% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $121.3M | $173.2M |
| Total Long-Term Liabilities | $16.64M | $16.38M |
| Total Liabilities | $536.0M | $589.5M |
| YoY Change | -13.54% | -4.78% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$1.332B | -$1.262B |
| YoY Change | 12.3% | 14.64% |
| Common Stock | $8.000K | $8.000K |
| YoY Change | 14.29% | 14.29% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $15.15M | $74.07M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $551.1M | $663.5M |
| YoY Change | -25.16% | -17.9% |
Cashflow Statement
| Concept | 2024 Q2 | 2024 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$70.41M | -$136.1M |
| YoY Change | -17.78% | 57.6% |
| Depreciation, Depletion And Amortization | $10.35M | $9.880M |
| YoY Change | -25.6% | 3.51% |
| Cash From Operating Activities | -$40.24M | -$119.0M |
| YoY Change | -41.93% | 46.71% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $76.99M | $0.00 |
| YoY Change | 1907.12% | -100.0% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $105.6M | $111.4M |
| YoY Change | -635.59% | -1327.56% |
| Cash From Investing Activities | $28.61M | $104.9M |
| YoY Change | -221.47% | -383.21% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 782.0K | -$525.0K |
| YoY Change | -65.49% | -100.24% |
| NET CHANGE | ||
| Cash From Operating Activities | -40.24M | -$119.0M |
| Cash From Investing Activities | 28.61M | $104.9M |
| Cash From Financing Activities | 782.0K | -$525.0K |
| Net Change In Cash | -10.85M | -$14.93M |
| YoY Change | -88.02% | -114.97% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$40.24M | -$119.0M |
| Capital Expenditures | $76.99M | $0.00 |
| Free Cash Flow | -$117.2M | -$119.0M |
| YoY Change | 60.31% | 45.58% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2023Q1 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
|
10233000 | usd |
| CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
41374000 | usd |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
30888000 | usd |
| CY2024Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
1504000 | usd |
| CY2023Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
4145000 | usd |
| CY2024Q1 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
49420000 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
58162000 | usd |
| CY2024Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
64223000 | usd |
| CY2023Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
65950000 | usd |
| CY2024Q1 | tvtx |
In Process Research And Development Expense
InProcessResearchAndDevelopmentExpense
|
65205000 | usd |
| CY2023Q1 | tvtx |
In Process Research And Development Expense
InProcessResearchAndDevelopmentExpense
|
0 | usd |
| CY2024Q1 | us-gaap |
Restructuring Charges
RestructuringCharges
|
259000 | usd |
| CY2023Q1 | us-gaap |
Restructuring Charges
RestructuringCharges
|
0 | usd |
| CY2024Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
180611000 | usd |
| CY2023Q1 | us-gaap |
Costs And Expenses
CostsAndExpenses
|
128257000 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-139237000 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-97369000 | usd |
| CY2024Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
6032000 | usd |
| CY2023Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
3646000 | usd |
| CY2024Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-2800000 | usd |
| CY2023Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-2850000 | usd |
| CY2024Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
238000 | usd |
| CY2023Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
87000 | usd |
| CY2024Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
3470000 | usd |
| CY2023Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
883000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-135767000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-96486000 | usd |
| CY2024Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
191000 | usd |
| CY2023Q1 | us-gaap |
Income Tax Expense Benefit
IncomeTaxExpenseBenefit
|
78000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-135958000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-96564000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
|
-103000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-136061000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-86331000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
-1.76 | |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
-1.76 | |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
-1.42 | |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
-1.42 | |
| CY2024Q1 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
|
0 | |
| CY2024Q1 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
|
0 | |
| CY2023Q1 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
|
0.15 | |
| CY2023Q1 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
|
0.15 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.76 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.76 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.27 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.27 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
77136493 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
77136493 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
68174099 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
68174099 | shares |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-136061000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-86331000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
629000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
-566000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
-1065000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
|
1297000 | usd |
| CY2024Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-136497000 | usd |
| CY2023Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-85600000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
200810000 | usd |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
42851000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
9420000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
13325000 | usd |
| CY2024Q1 | us-gaap |
Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
|
0 | usd |
| CY2023Q1 | us-gaap |
Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
|
2296000 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
|
338000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
|
439000 | usd |
| CY2024Q1 | tvtx |
Pre Funded Common Stock Warrants Net Of Issuance Costs
PreFundedCommonStockWarrantsNetOfIssuanceCosts
|
1600000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
24630000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
629000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
|
-566000 | usd |
| CY2024Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
-1065000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
|
1297000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-136061000 | usd |
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
74071000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
189140000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-136061000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-86331000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
|
-103000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
|
10233000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-135958000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-96564000 | usd |
| CY2024Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
9880000 | usd |
| CY2023Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
6620000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
9758000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
13471000 | usd |
| CY2024Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-364000 | usd |
| CY2023Q1 | us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
1097000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
1547000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
4658000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
1824000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
510000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2724000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2599000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-24841000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
-351000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
21474000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-8879000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-1522000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-3844000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
8038000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-238000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-118902000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-98649000 | usd |
| CY2024Q1 | us-gaap |
Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
|
-103000 | usd |
| CY2023Q1 | us-gaap |
Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
|
17532000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-119005000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-81117000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
111364000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
94118000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
0 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
103190000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
0 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
630000 | usd |
| CY2024Q1 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
6466000 | usd |
| CY2023Q1 | us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
27337000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
104898000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-37039000 | usd |
| CY2024Q1 | tvtx |
Payment Of Guaranteed Minimum Royalty
PaymentOfGuaranteedMinimumRoyalty
|
525000 | usd |
| CY2023Q1 | tvtx |
Payment Of Guaranteed Minimum Royalty
PaymentOfGuaranteedMinimumRoyalty
|
525000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
0 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
24630000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
2296000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
-525000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
217600000 | usd |
| CY2024Q1 | us-gaap |
Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
|
0 | usd |
| CY2023Q1 | us-gaap |
Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
|
-604000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-525000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
216996000 | usd |
| CY2024Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-293000 | usd |
| CY2023Q1 | us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
848000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-14925000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
99688000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
58176000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
61688000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
43251000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
161376000 | usd |
| CY2024Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
DESCRIPTION OF BUSINESS<div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#006ebf;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Organization and Description of Business</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Travere Therapeutics, Inc. (“we”, “our”, “us”, “Travere” and the “Company”) refers to Travere Therapeutics, Inc., a Delaware corporation, as well as its subsidiaries. Travere is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on identifying, developing and delivering life-changing therapies to people living with rare kidney and metabolic diseases. The Company regularly evaluates and, where appropriate, acts on opportunities to expand its product pipeline through licenses and acquisitions of products in areas that will serve patients with serious </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">unmet medical need</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and that the Company believes offer attractive growth characteristics.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#006ebf;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discontinued Operations - Sale of Bile Acid Product Portfolio</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In July 2023, Travere entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Mirum Pharmaceuticals, Inc. ("Mirum Pharmaceuticals" or “Mirum”), pursuant to which Mirum agreed to purchase from Travere substantially all of the assets primarily related to Travere’s business of development, manufacture (including synthesis, formulation, finishing or packaging) and commercialization of Chenodal and Cholbam (also known as Kolbam, and together with Chenodal, the “Products”), collectively, the "bile acid business". On August 31, 2023, the Company and Mirum consummated the transactions contemplated by the Purchase Agreement (the “Closing”). In connection with the Closing, Mirum paid Travere an upfront cash payment of $210.0 million. Pursuant to the Purchase Agreement, after the Closing, Travere is eligible to receive up to $235.0 million upon the achievement of certain milestones based on specified amounts of annual net sales (tiered from $125.0 million to $500.0 million) of the Products. The Company has reflected the bile acid business as a discontinued operation in the unaudited consolidated financial statements for all periods presented. See Note 18 for further discussion. </span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Unless otherwise noted, amounts and disclosures throughout the Notes to the unaudited consolidated financial statements relate to the Company's continuing operations.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Approved Products:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#006ebf;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FILSPARI® (sparsentan)</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 17, 2023, the U.S. Food and Drug Administration (the "FDA") granted accelerated approval of FILSPARI® (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a UPCR ≥1.5 gram/gram. FILSPARI, a once-daily, oral medication is designed to selectively target two critical pathways (endothelin 1 and angiotensin-II) in the disease progression of IgAN. </span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">This indication was granted under accelerated approval based on reduction in proteinuria. The continued approval of FILSPARI may be contingent upon confirmation of a clinical benefit in the Company's Phase 3 clinical trial of sparsentan for the treatment of IgAN (the "PROTECT Study"). In September 2023, the Company announced topline two-year confirmatory secondary endpoint results from the PROTECT Study and in December 2023, the Company announced the completion of a successful pre-NDA meeting with the FDA for FILSPARI in IgAN. In March 2024, the Company submitted a supplemental New Drug Application (sNDA) for conversion of the existing U.S. accelerated approval of FILSPARI to full approval. In May 2024, the Company announced that the FDA has accepted and granted Priority Review of its sNDA to convert FILSPARI from accelerated approval to full approval for the treatment of IgAN in the U.S. The FDA assigned a Prescription Drug User Fee Act (“PDUFA”) target action date of September 5, 2024.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In April 2024, the Company and Vifor (International) Ltd. ("CSL Vifor"), with whom the Company entered into a license and collaboration agreement ("License Agreement") in September 2021, announced that the European Commission has granted conditional marketing authorization (“CMA”) for FILSPARI (sparsentan) for the treatment of adults with primary IgAN with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). The CMA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway. The European Commission's decision follows the positive opinion from the Committee for Medicinal Products for Human Use (“CHMP”) in February 2024, based on results from the pivotal Phase 3 PROTECT Study of FILSPARI in IgAN. Under the terms of the License Agreement, the Company will be entitled to receive a regulatory milestone payment of $17.5 million upon receipt of full regulatory approval by the European Commission for IgAN, and an additional milestone payment upon achievement of market access initiatives in certain countries. The Company also expects to make a milestone payment of $5.8 million to Ligand Pharmaceuticals in the second quarter of 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#006ebf;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Thiola® and Thiola EC® (tiopronin tablets)</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thiola® and Thiola EC® (tiopronin tablets) are approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</span></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical-Stage Programs:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#006ebf;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sparsentan for the treatment of FSGS</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Sparsentan remains a novel investigational product candidate which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis (FSGS) in the U.S. and the EEA. In December 2023, the Company announced that it had completed its planned Type C meeting with the FDA to discuss previously reported results from the Phase 3 DUPLEX Study of sparsentan in FSGS. The FDA acknowledged the high unmet need for approved therapies as well as the challenges in studying FSGS but indicated that the two-year results from the Phase 3 DUPLEX Study alone were not sufficient to support an sNDA submission. Together with CSL Vifor, the Company also plans to engage with the EMA to determine the potential for a subsequent variation to the CMA of sparsentan for the treatment of FSGS, subject to a review decision on the pending application for CMA of sparsentan in </span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">IgAN. The Company is conducting additional analyses of FSGS data and intends to engage with regulators to evaluate potential regulatory pathways for a sparsentan FSGS indication.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#006ebf;font-family:'Arial Narrow',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pegtibatinase</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pegtibatinas</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">e is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU). Pegtibatinase has been granted Rare Pediatric Disease, Fast Track and Breakthrough Therapy designations by the FDA, as well as orphan drug designation in the United States and European Union. In May 2023, the Company announced positive topline results from cohort 6 in the Phase 1/2 COMPOSE Study. </span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In December 2023, the Company initiated the pivotal Phase 3 HARMONY Study to support the potential approval of pegtibatinase for the treatment of classical HCU. The HARMONY Study is a global, randomized, multi-center, double-blind, placebo-controlled Phase 3 clinical trial designed to evaluate the efficacy and safety of pegtibatinase as a novel treatment to reduce total homocysteine (tHcy) levels. In the beginning of 2024, the first patients were dosed in the HARMONY Study. Topline results from the HARMONY Study are expected in 2026. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> acquired pegtibatinase as part of the November 2020 acquisition of Orphan Technologies Limited.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#666666;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical Programs:</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is a participant in a Cooperative Research and Development Agreement ("CRADA"), which forms a multi-stakeholder approach to pool resources with leading experts and incorporate the patient perspective early in the therapeutic identification and development process. The Company is partnering with the National Institutes of Health’s National Center for Advancing Translational Sciences ("NCATS") and a leading patient advocacy organization, Alagille Syndrome Alliance, aimed at the identification of potential small molecule therapeutics for Alagille syndrome ("ALGS"). There are no treatment options currently approved for ALGS.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial Narrow',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is party to a collaboration agreement with PharmaKrysto Limited and their early-stage cystinuria discovery program, whereby the Company is responsible for funding all research and development expenses for the pre-clinical activities associated with the cystinuria program.</span></div> | |
| CY2024Q1 | tvtx |
Debt Securities Availableforsale Amortized Cost Basis Current
DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent
|
241871000 | usd |
| CY2024Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
1504000 | usd |
| CY2023Q1 | us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
4145000 | usd |
| CY2024Q1 | tvtx |
Number Of Phase One Half Clinical Trials In Process
NumberOfPhaseOneHalfClinicalTrialsInProcess
|
1 | clinicaltrial |
| CY2024Q1 | tvtx |
Number Of Phase Three Clinical Trials In Process
NumberOfPhaseThreeClinicalTrialsInProcess
|
3 | clinicaltrial |
| us-gaap |
Restructuring Costs
RestructuringCosts
|
11700000 | usd | |
| CY2024Q1 | us-gaap |
Restructuring Costs
RestructuringCosts
|
300000 | usd |
| CY2024Q1 | us-gaap |
Restructuring Reserve Current
RestructuringReserveCurrent
|
1200000 | usd |
| CY2023Q4 | us-gaap |
Restructuring Reserve Current
RestructuringReserveCurrent
|
11400000 | usd |
| CY2024Q1 | us-gaap |
Payments For Restructuring
PaymentsForRestructuring
|
10500000 | usd |
| CY2023Q4 | us-gaap |
Restructuring Reserve
RestructuringReserve
|
11421000 | usd |
| CY2022Q4 | us-gaap |
Restructuring Reserve
RestructuringReserve
|
0 | usd |
| CY2024Q1 | us-gaap |
Restructuring Charges
RestructuringCharges
|
259000 | usd |
| CY2023Q1 | us-gaap |
Restructuring Charges
RestructuringCharges
|
0 | usd |
| CY2024Q1 | us-gaap |
Payments For Restructuring
PaymentsForRestructuring
|
10502000 | usd |
| CY2023Q1 | us-gaap |
Payments For Restructuring
PaymentsForRestructuring
|
0 | usd |
| CY2024Q1 | us-gaap |
Restructuring Reserve Translation Adjustment
RestructuringReserveTranslationAdjustment
|
26000 | usd |
| CY2023Q1 | us-gaap |
Restructuring Reserve Translation Adjustment
RestructuringReserveTranslationAdjustment
|
0 | usd |
| CY2024Q1 | us-gaap |
Restructuring Reserve
RestructuringReserve
|
1204000 | usd |
| CY2023Q1 | us-gaap |
Restructuring Reserve
RestructuringReserve
|
0 | usd |
| CY2024Q1 | tvtx |
Number Of Direct To Patient Pharmacies Sold To
NumberOfDirectToPatientPharmaciesSoldTo
|
3 | pharmacy |
| CY2024Q1 | us-gaap |
Revenue Performance Obligation Description Of Timing
RevenuePerformanceObligationDescriptionOfTiming
|
For FILSPARI, sales are recognized upon delivery of the product to the specialty pharmacies. The Company receives payments from its FILSPARI sales based on terms that are generally 30 days from shipment of the product to the specialty pharmacy. For the Company's other products, product sales are recognized upon delivery to the patient. The Company receives payments from sales of its other products, primarily through third party payers, based on terms that generally are within 30 days of delivery of product to the patient. | |
| CY2024Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
397793000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
508675000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
6889000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
7064000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
4781000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
30297000 | usd |
| CY2024Q1 | tvtx |
Debt Securities Available For Sale Unrealized Gain Current
DebtSecuritiesAvailableForSaleUnrealizedGainCurrent
|
76000 | usd |
| CY2024Q1 | tvtx |
Debt Securities Available For Sale Unrealized Loss Current
DebtSecuritiesAvailableForSaleUnrealizedLossCurrent
|
588000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
241359000 | usd |
| CY2024Q1 | tvtx |
Debt Securities Availableforsale Amortized Cost Basis Noncurrent
DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent
|
156245000 | usd |
| CY2024Q1 | tvtx |
Debt Securities Available For Sale Unrealized Gain Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent
|
364000 | usd |
| CY2024Q1 | tvtx |
Debt Securities Available For Sale Unrealized Loss Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent
|
175000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
156434000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
398116000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
440000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
763000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
397793000 | usd |
| CY2023Q4 | tvtx |
Debt Securities Availableforsale Amortized Cost Basis Current
DebtSecuritiesAvailableforsaleAmortizedCostBasisCurrent
|
249247000 | usd |
| CY2023Q4 | tvtx |
Debt Securities Available For Sale Unrealized Gain Current
DebtSecuritiesAvailableForSaleUnrealizedGainCurrent
|
90000 | usd |
| CY2023Q4 | tvtx |
Debt Securities Available For Sale Unrealized Loss Current
DebtSecuritiesAvailableForSaleUnrealizedLossCurrent
|
699000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
248638000 | usd |
| CY2023Q4 | tvtx |
Debt Securities Availableforsale Amortized Cost Basis Noncurrent
DebtSecuritiesAvailableforsaleAmortizedCostBasisNoncurrent
|
258687000 | usd |
| CY2023Q4 | tvtx |
Debt Securities Available For Sale Unrealized Gain Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedGainNoncurrent
|
1550000 | usd |
| CY2023Q4 | tvtx |
Debt Securities Available For Sale Unrealized Loss Noncurrent
DebtSecuritiesAvailableForSaleUnrealizedLossNoncurrent
|
200000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
|
260037000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
507934000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
1640000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
899000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
508675000 | usd |
| CY2024Q1 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
3800000 | usd |
| CY2023Q4 | us-gaap |
Interest Receivable Current
InterestReceivableCurrent
|
4600000 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
|
150058000 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
449000 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
|
66897000 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
|
314000 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
216955000 | usd |
| CY2024Q1 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
|
763000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
|
227533000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
|
639000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
|
41315000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
|
260000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
|
268848000 | usd |
| CY2023Q4 | us-gaap |
Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
|
899000 | usd |
| CY2024Q1 | tvtx |
Debt Securities Available For Sale Unrealized Loss Position Amortized Cost
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCost
|
217700000 | usd |
| CY2023Q4 | tvtx |
Debt Securities Available For Sale Unrealized Loss Position Amortized Cost
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAmortizedCost
|
269700000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
|
P5Y | |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
4890000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
6673000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
3974000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
26323000 | usd |
| CY2024Q1 | tvtx |
Operating Lease Incentive Tenant Improvements
OperatingLeaseIncentiveTenantImprovements
|
4345000 | usd |
| CY2024Q1 | tvtx |
Straight Line Lease Expense In Excess Of Cash Payments
StraightLineLeaseExpenseInExcessOfCashPayments
|
4707000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
17271000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P4Y4M24D | |
| CY2023Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P4Y8M12D | |
| CY2024Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0648 | |
| CY2023Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.0648 | |
| CY2024Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
1200000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
1200000 | usd |
| CY2024Q1 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
43251000 | usd |
| CY2024Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
397793000 | usd |
| CY2024Q1 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
441044000 | usd |
| CY2023Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
58176000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
508675000 | usd |
| CY2023Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
566851000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
189128000 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
183037000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
88699000 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
|
79347000 | usd |
| CY2024Q1 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
100429000 | usd |
| CY2023Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
103690000 | usd |
| CY2024Q1 | us-gaap |
Goodwill
Goodwill
|
800000 | usd |
| CY2023Q4 | us-gaap |
Goodwill
Goodwill
|
800000 | usd |
| CY2024Q1 | tvtx |
Sales Discounts Rebates And Allowances Current
SalesDiscountsRebatesAndAllowancesCurrent
|
11633000 | usd |
| CY2023Q4 | tvtx |
Sales Discounts Rebates And Allowances Current
SalesDiscountsRebatesAndAllowancesCurrent
|
13730000 | usd |
| CY2024Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
9352000 | usd |
| CY2023Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
6062000 | usd |
| CY2022Q1 | tvtx |
Debt Instrument Repurchase Amount Including Accrued And Unpaid Interest
DebtInstrumentRepurchaseAmountIncludingAccruedAndUnpaidInterest
|
213800000 | usd |
| CY2023Q1 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-7600000 | usd |
| CY2023Q1 | us-gaap |
Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
|
3400000 | usd |
| CY2024Q1 | us-gaap |
Interest Expense
InterestExpense
|
2800000 | usd |
| CY2023Q1 | us-gaap |
Interest Expense
InterestExpense
|
2900000 | usd |
| CY2024Q1 | tvtx |
Accrued Milestone Payments Current
AccruedMilestonePaymentsCurrent
|
65000000 | usd |
| CY2023Q4 | tvtx |
Accrued Milestone Payments Current
AccruedMilestonePaymentsCurrent
|
0 | usd |
| CY2024Q1 | tvtx |
Accrued Liabilities Researchand Development Current
AccruedLiabilitiesResearchandDevelopmentCurrent
|
20861000 | usd |
| CY2023Q4 | tvtx |
Accrued Liabilities Researchand Development Current
AccruedLiabilitiesResearchandDevelopmentCurrent
|
26006000 | usd |
| CY2024Q1 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
18715000 | usd |
| CY2023Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
29908000 | usd |
| CY2024Q1 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
6686000 | usd |
| CY2023Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
6991000 | usd |
| CY2024Q1 | tvtx |
Accrued Liabilities Selling Generaland Administrative Current
AccruedLiabilitiesSellingGeneralandAdministrativeCurrent
|
5893000 | usd |
| CY2023Q4 | tvtx |
Accrued Liabilities Selling Generaland Administrative Current
AccruedLiabilitiesSellingGeneralandAdministrativeCurrent
|
7190000 | usd |
| CY2024Q1 | us-gaap |
Restructuring Reserve Current
RestructuringReserveCurrent
|
1204000 | usd |
| CY2023Q4 | us-gaap |
Restructuring Reserve Current
RestructuringReserveCurrent
|
11421000 | usd |
| CY2024Q1 | tvtx |
Transition Services Accrual Current
TransitionServicesAccrualCurrent
|
605000 | usd |
| CY2023Q4 | tvtx |
Transition Services Accrual Current
TransitionServicesAccrualCurrent
|
12282000 | usd |
| CY2024Q1 | tvtx |
Accrued Liabilities Miscellaneous Current
AccruedLiabilitiesMiscellaneousCurrent
|
8983000 | usd |
| CY2023Q4 | tvtx |
Accrued Liabilities Miscellaneous Current
AccruedLiabilitiesMiscellaneousCurrent
|
11463000 | usd |
| CY2024Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
139580000 | usd |
| CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
118991000 | usd |
| CY2024Q1 | tvtx |
Weighted Average Number Of Shares Outstanding Diluted Continuing Operations
WeightedAverageNumberOfSharesOutstandingDilutedContinuingOperations
|
77136493 | shares |
| CY2024Q1 | tvtx |
Weighted Average Number Of Shares Outstanding Basic Continuing Operations
WeightedAverageNumberOfSharesOutstandingBasicContinuingOperations
|
77136493 | shares |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-135958000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
-1.76 | |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
-1.76 | |
| CY2023Q1 | tvtx |
Weighted Average Number Of Shares Outstanding Basic Continuing Operations
WeightedAverageNumberOfSharesOutstandingBasicContinuingOperations
|
68174099 | shares |
| CY2023Q1 | tvtx |
Weighted Average Number Of Shares Outstanding Diluted Continuing Operations
WeightedAverageNumberOfSharesOutstandingDilutedContinuingOperations
|
68174099 | shares |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
|
-96564000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
|
-1.42 | |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
|
-1.42 | |
| CY2024Q1 | tvtx |
Weighted Average Number Of Shares Outstanding Diluted Discontinued Operations
WeightedAverageNumberOfSharesOutstandingDilutedDiscontinuedOperations
|
77136493 | shares |
| CY2024Q1 | tvtx |
Weighted Average Number Of Shares Outstanding Basic Discontinued Operations
WeightedAverageNumberOfSharesOutstandingBasicDiscontinuedOperations
|
77136493 | shares |
| CY2024Q1 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
|
-103000 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
|
0 | |
| CY2024Q1 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
|
0 | |
| CY2023Q1 | tvtx |
Weighted Average Number Of Shares Outstanding Basic Discontinued Operations
WeightedAverageNumberOfSharesOutstandingBasicDiscontinuedOperations
|
68174099 | shares |
| CY2023Q1 | tvtx |
Weighted Average Number Of Shares Outstanding Diluted Discontinued Operations
WeightedAverageNumberOfSharesOutstandingDilutedDiscontinuedOperations
|
68174099 | shares |
| CY2023Q1 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity
IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
|
10233000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
|
0.15 | |
| CY2023Q1 | us-gaap |
Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
|
0.15 | |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
9758000 | usd |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
77136493 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
77136493 | shares |
| CY2024Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-136061000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-136061000 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.76 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.76 | |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
68174099 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
68174099 | shares |
| CY2023Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-86331000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-86331000 | usd |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.27 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.27 | |
| CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
26395000 | shares |
| CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
25523529 | shares |
| CY2024Q1 | tvtx |
In Process Research And Development Expense
InProcessResearchAndDevelopmentExpense
|
65200000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
8200000 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
20.99 | |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
13471000 | usd |
| CY2024Q1 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
29838000 | usd |
| CY2023Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
33790000 | usd |
| CY2024Q1 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
9329000 | usd |
| CY2023Q4 | us-gaap |
Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
|
4727000 | usd |
| CY2024Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
3139000 | usd |
| CY2023Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
2387000 | usd |
| CY2024Q1 | us-gaap |
Inventory Net
InventoryNet
|
42306000 | usd |
| CY2023Q4 | us-gaap |
Inventory Net
InventoryNet
|
40904000 | usd |
| CY2024Q1 | us-gaap |
Inventory Gross
InventoryGross
|
4532000 | usd |
| CY2023Q4 | us-gaap |
Inventory Gross
InventoryGross
|
9410000 | usd |
| CY2024Q1 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
37774000 | usd |
| CY2023Q4 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
31494000 | usd |
| CY2024Q1 | us-gaap |
Inventory Net
InventoryNet
|
42306000 | usd |
| CY2023Q4 | us-gaap |
Inventory Net
InventoryNet
|
40904000 | usd |
| CY2024Q1 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
22700000 | usd |
| CY2023Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
21200000 | usd |
| CY2024Q1 | tvtx |
Transition Services Accruals Current
TransitionServicesAccrualsCurrent
|
600000 | usd |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false |
